Next Article in Journal
Drug–Drug Interactions, Medication Adherence, and Stroke Should Be Considered When Approaching the Impact of Acid Suppression Therapy on Chronic Kidney Disease Patients. Comment on Chen et al. Impact of Acid Suppression Therapy on Renal and Survival Outcomes in Patients with Chronic Kidney Disease: A Taiwanese Nationwide Cohort Study. J. Clin. Med. 2022, 11, 5612
Next Article in Special Issue
Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome
Previous Article in Journal
Dynamic Morphology of the Ascending Aorta and Its Implications for Proximal Landing in Thoracic Endovascular Aortic Repair
Previous Article in Special Issue
Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 1
10.3390/jcm12010071
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis

by
Miguel Marín-Rosales
1,2,
Claudia Azucena Palafox-Sánchez
2,3,*,
Ramón Antonio Franco-Topete
4,
Francisco Josué Carrillo-Ballesteros
5,
Alvaro Cruz
3,
Diana Celeste Salazar-Camarena
2,
José Francisco Muñoz-Valle
3 and
Francisco Ramos-Solano
4
1
Departamento de Reumatología, Hospital General de Occidente, Secretaría de Salud Jalisco, Guadalajara 45170, Mexico
2
Grupo de Inmunología Molecular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
3
Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
4
Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
5
Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Mexico
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(1), 71; https://doi.org/10.3390/jcm12010071
Submission received: 23 November 2022 / Revised: 16 December 2022 / Accepted: 18 December 2022 / Published: 22 December 2022
(This article belongs to the Special Issue Systemic Lupus Erythematosus: Pathogenesis, Diagnosis and Treatment)
Browse Figures
Versions Notes

Abstract

:
Background: The B-cell activating factor (BAFF) controls the maturation and survival of B cells. An imbalance in this cytokine has been associated with systemic autoimmunity in SLE and lupus nephritis (LN). However, few investigations have evaluated the tissular expression of BAFF in LN. This study aimed to associate BAFF system expression at the tissular level with the proliferative LN classes. Methods: The analysis included eighteen kidney tissues, with sixteen LN (class III = 5, class IV = 6, class III/IV+V = 4, and class V = 1), and two controls. The tissular expression was evaluated with an immunochemistry assay. A Cytation5 imaging reader and ImageJ software were used to analyze the quantitative expression. A p-value < 0.05 was considered significant. Results: The expressions of BAFF, A proliferation-inducing ligand (APRIL), and their receptors were observed in glomerular, tubular, and interstitial zones, with BAFF being the most strongly expressed in the overall analysis. BAFF-Receptor (BR3), transmembrane activator and CALM interactor (TACI), and B-Cell maturation antigen (BCMA) displayed higher expressions in LN class IV in all zones analyzed (p < 0.05). Additionally, a positive correlation was found between APRIL, TACI, and BCMA at the glomerular level; BCMA and APRIL in the interstitial zone; and BR3, TACI, and BCMA in the tubule (p < 0.05). Conclusions: The expression of BAFF and BAFF receptors is mainly associated with LN class IV, emphasizing the participation of these receptors as an essential pathogenic factor in kidney involvement in SLE patients.

1. Introduction

Lupus nephritis (LN) is the most frequent life-threatening clinical domain of systemic lupus erythematosus (SLE); renal involvement affects 30–70% of patients and shows high frequency and severity in Black and Latin-American Hispanic populations [1,2]. LN diagnosis is sustained based on clinical features and an evaluation of conventional biomarkers such as low complement serum concentration, high anti-dsDNA antibodies, and urinary findings [3,4]. However, kidney biopsy is the diagnostic gold standard and guides LN treatment, according to the 2003 International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification [5,6].
B-cell ontogeny is controlled through the BAFF system; this system is integrated by B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and their receptors, namely BAFF-Receptor (BR3), transmembrane activator and CALM interactor (TACI), and B-Cell maturation antigen (BCMA). BAFF and APRIL belong to the tumor necrosis factor (TNF) family and promote B-cell activation, proliferation, maturation, and survival through BR3, TACI, and BCMA receptors [7,8,9,10,11].
An imbalance in BAFF, APRIL, or their receptors in both murine models and humans has been associated with the development of autoimmune diseases, including SLE, Sjögren’s Syndrome, and rheumatoid arthritis [11,12,13,14,15,16,17,18]. Regarding SLE, the serum concentration of BAFF and APRIL has been reported to be higher in SLE patients; these ligands were previously associated with the disease activity index and autoantibody levels and can predict a flare [13,14,19,20,21,22,23,24,25]. On the other hand, the soluble BCMA serum concentration was found to have a higher concentration and was correlated with the activity index in SLE patients [25]. Regarding the BAFF receptors, BR3, TACI, and BCMA were identified in CD3 T cells in SLE patients, and their expression varies according to SLE disease activity [21,23,25].
Given the growing need for diagnostic tools for LN, multiple new biomarkers have been associated with this domain [26], and BAFF and APRIL have been linked with renal activity in Mexican SLE patients [22,23]. Additionally, BAFF and their receptors were analyzed in situ in kidney tissues of LN patients, showing differential pattern expression according to LN classes [27]. However, the analysis did not include APRIL. Based on the association of the BAFF system with renal involvement, the poor renal prognosis for proliferative LN in Latin American SLE patients, and the small number of validated renal biomarkers, this study evaluated the renal tissue expression of BAFF, APRIL, BR3, TACI, and BCMA in patients with proliferative LN.

2. Materials and Methods

2.1. Study Tissues

A retrospective and descriptive study were conducted. This study included sixteen kidney tissues of LN patients classified as class III, IV, V, or V/III-IV according to the 2003 ISN/RPS classification [5]. All LN patients met the 2012 Systemic Lupus International Collaborating Clinics classification criteria for SLE [28] and were recruited at the rheumatology department of Hospital General de Occidente. Additionally, two kidney incisional biopsies without autoimmunity histopathological features were used as controls. All patients provided written informed consent according to the 2013 Declaration of Helsinki and actual national guidelines of the Health Ministry. The ethics and research committees of the Hospital General de Occidente, Jalisco, Mexico, approved the study under the number CI-561/18.

2.2. Immunohistochemical Staining

Kidney biopsies were fixed in 4% paraformaldehyde and embedded in paraffin using a tissue processor (TP1020; Leica Biosystems, Wetzlar, Germany). Tissues were sectioned at 5 µm, mounted on electrocharged slides, and deparaffinized at 60 °C for 30 min in a Dako Hybridizer (Dako Colorado Inc. Collins, CO, USA). Posteriorly, the tissues were rehydrated by immersion in xylene using graded ethanol dilutions followed by distilled water. According to Carrillo-Ballesteros et al., the immunohistochemical assay was standardized in amygdaline tissue [29]. Briefly, after rehydration of the tissue, epitope retrieval was performed with the Dako PT Link system (Dako Colorado Inc. Collins, CO, USA) at 90 degrees for 30 min, and the slides were submerged into the Dako PT Link cameras with a 1 mM EDTA buffer (pH = 9) for BAFF, APRIL, and BR3, as well as a 10 mM sodium citrate buffer (pH = 6) for TACI and BCMA. Later, all slides were cooled, and a 3% hydrogen peroxide—10% methanol solution was added to achieve an endogenous peroxidase blockade. Posteriorly, slides were incubated for 30 min with the following primary antibodies: rat monoclonal antibody to BAFF (Abcam, cat. no. ab16081, dilution 1:100), rabbit polyclonal antibody to APRIL (Abcam, cat. no. ab189263, dilution 1:50), mouse monoclonal antibody to BR3 (Abcam, cat. no. ab16232, dilution 1:250), rabbit polyclonal antibody to TACI (Abcam, cat. no. ab79023, dilution 1:100), and rabbit polyclonal antibody to BCMA (Abcam, cat. no. ab5972, dilution 1:100). Following incubation with primary antibodies and buffer washing, the slides were incubated for 10 min with the universal post-primary antibody included in the BOND polymer refine detection system (Leica Biosystems, cat. no. DS9800), and diaminobenzidine (DAB) was employed for detection until the development of a red-brown color. Finally, slides were counterstained with Harris hematoxylin and reviewed under a microscope by two experienced pathologists.

2.3. Immunohistochemical Image Processing and Statistical Analysis

After slide tissue staining, three renal structures (glomerulus, tubule, and interstitial) were photographed in triplicate using a BioTek Citation|5 Cell Imaging Multimode Reader (Santa Clara, CA, USA) with 10× and 20× magnification. Later, the ImageJ v1.51j8 and DAB deconvolution plugin software (National Institute of Health, Bethesda, MD, USA. https://imagej.nih.gov/ij/, accessed on 15 January 2021) was used to analyze the photos and obtain the immunoreaction score. In the DAB layer, the pixel intensity value was represented in a range of 0–255 (the darkest shade and lightest shade represent 0 and 255, respectively), according to Chatterjee et al. [30]. The mean intensity default threshold was set in the ImageJ software under the “Image” menu using the “measure” tool from the “Analyze” menu. Later, the percentage of positive pixels was determined in the selected areas. Descriptive analysis included the median, interquartile range (IQR), and frequencies. Additionally, Fisher, Chi-square, Mann–Whitney U, Kruskal–Wallis and Dunn’s post hoc, and Spearman correlation tests were used as appropriate. A p-value < 0.05 was considered significant.

3. Results

3.1. Histopathological Features of LN

Eighteen kidney tissues were included, including sixteen percutaneous biopsies of patients with LN, and two incisional biopsies were obtained by necropsy without histopathological features of autoimmunity. Thirteen (81%) LN cases were women, class IV represented 38% (6/16) of the cases, class III and class V+III/IV were 31% (5/16) and 25% (4/16) of the cases, respectively, and only 6% (1/16) were classified as class V. The wire-loop lesions and total renal activity index were associated with proliferative diffuse LN (p < 0.05). Table 1 shows all histopathological findings.

3.2. Renal BAFF System Expression and Association with LN Classes

The LN tissues showed BAFF system expression at the glomerular, tubule, and interstitial levels. BAFF and BCMA were expressed in the glomerular epithelium membrane of the glomerulus, and TACI presented expression in glomerular resident cells. BAFF, APRIL, TACI, and BCMA were expressed at the tubular level, mainly in the cytoplasm of the tubular epithelium. Additionally, BR3, TACI, and BCMA demonstrated expression in inflammatory cells at an interstitial level. The control kidney tissues showed low BAFF expression in the tubular system, and APRIL, BR3, TACI, and BCMA were not expressed. Figure 1 shows BAFF system expression in tissues with LN and renal controls.
Based on the previous findings, ImageJ software was used to perform a quantitative expression analysis. For the LN tissues, the overall analysis indicated a higher percentage of BAFF expression [13.07% (IQR 9.62–19.91%)] than APRIL [8.86 (IQR 3.28–12.95%)], BR3 [6.93% (IQR 3.40–15.07%)], and BCMA [9.80 (IQR 5.32–12.95%)], with statistical significance (p < 0.05). Additionally, TACI [10.66% (IQR 7.74%–14.11%)] had higher expression than APRIL (p < 0.05) (see Figure 2d).
After the overall analysis, the LN tissues were stratified according to the ISN/RPS 2003 classification, and BAFF system expression was evaluated in three zones: glomerulus, tubule, and interstitium. At the glomerular level, both ligands and the three BAFF receptors exhibited similar expression between the renal control and LN classes (Figure 3a–e). However, the classes of LN demonstrated different receptor pattern expressions, showing higher expressions of BR3, TACI, and BCMA in classes IV (Figure 3c–e).
Similarly, the tubular zone was analyzed. BAFF, BR3, and TACI showed a higher percentage of expression than the renal controls, with statistical significance (Figure 3f,h,i). On the other hand, the tubular zone commonly expressed more APRIL and BCMA; however, no statistical significance was found (Figure 3g,j). When comparing BAFF system expression according to LN classes, classes IV and V+III/IV nephritis exhibited greater BR3, TACI, and BCMA expressions than the focal proliferative class (Figure 3h–j). In contrast, class III presented a higher expression of BAFF for another kind of nephritis (Figure 3a).
Additionally, expression analysis was performed in the interstitial zone. BAFF, BR3, and TACI exhibited higher expressions in LN compared to the control with statistical significance (Figure 3k,m,n). Otherwise, APRIL and BCMA showed a trend toward higher expression than the kidney controls; however, no statistical significance was found (Figure 3l,o). In the LN classes sub-analysis, BAFF, BR3, and BCMA expressions were higher in diffuse proliferative nephritis than in focal and membranous lesions (Figure 3k,m,o). On the other hand, TACI and APRIL did not show statistical significance (Figure 3l,n).

3.3. Correlation of Renal BAFF System Expression

Subsequently, a correlation analysis of BAFF system expression was performed. At the glomerular level (Figure 4a), APRIL displayed positive correlations with BR3 (r2 = 0.64), TACI (r2 = 0.40), and BCMA (r2 = 0.66), with statistical significance (p < 0.05). Additionally, TACI and BCMA correlated positively (r2 = 0.40, p < 0.05, Figure 4b). On the other hand, the tubular expression (Figure 4b) of BR3, TACI, and BCMA showed a positive correlation [BR3/TACI (r2 = 0.44), BR3/BCMA (r2 = 0.51), and TACI/BCMA (r2 = 0.47), p < 0.05]. Additionally, analysis at the interstitial level (Figure 4c) demonstrated a positive correlation between APRIL and BCMA (r2 = 0.50), as well as between BCMA and TACI (r2 = 0.43), with statistical significance (p < 0.05).

4. Discussion

LN is the most frequent life-threatening complication among African and Latin American SLE patients. LN is considered a predictor of flare disease [31] and causes end-stage renal disease (ESRD) in 10–30% of cases [32]. Multiple conventional and new renal biomarkers have been associated with LN [26]. However, a kidney biopsy remains the diagnostic gold standard and guides treatment according to the histological findings.
This study associated the histopathological activity index and wire-loop lesions with LN-IV. The most frequent histopathological features were a full-house phenomenon, tubular tumefaction, tubular atrophy, and tubulointerstitial fibrosis. However, these typical pathological features for the diagnosis of LN had a sensitivity ranging from 68 to 80%, with a specificity of 80–96% [33]. On the other hand, fibrinoid necrosis, fibrous crescents, interstitial fibrosis, and tubular atrophy were associated with poor renal prognosis and ERSD [34]. Thus, searching for potential biomarkers for the diagnosis and treatment of LN is imperative.
BAFF system imbalance has been associated with LN and SLE flare [22,24]. BAFF, APRIL, and mRNA expression of these ligands have been identified at the urinary level in LN patients [35,36]. However, the serum and urinary concentrations did not show a correlation [35], and their links have not been elucidated. Thus, what is/are the sources of BAFF/APRIL at the urinary level?
Possible answers for the detection of both ligands at the urinary level include proteinuria associated with the loss of glomerular membrane integrity secondary to immune complex deposition. Additionally, the source of BAFF system ligands could be related to infiltrating immune cells and/or the local production of resident renal cells. This study identified the in situ expression of BAFF, APRIL, and their receptors in glomerular and tubular zones, as well as in inflammatory cells at the interstitial level in proliferative LN tissues, presenting similar findings to those reported by Suso et al. [27].
In murine models with LN, immune complex deposition induces the recruitment of immune cells, favoring BAFF secretion and altering the position of renal T cells. These events promote the formation of tertiary lymphoid structures [37]. Despite local BAFF overproduction, maintaining lymphoid structures requires chemokine CXCL13. In murine models, CXCL13 is secreted by podocytes in LN [38]; this chemokine has been associated with kidney graft rejection [39] and postulated as an allograft rejection biomarker [40]. However, this chemokine was not evaluated in the present study.
In addition to the role of podocytes related to murine nephritis, tubular epithelial cells could be involved in the BAFF system. All members of this system were expressed in the tubular epithelium in our study, showing a positive correlation between BR3, TACI, and BCMA receptors. Schwarting et al. associated tubular epithelial cells with ectopic BAFF overproduction and the histopathological activity index in LN. Additionally, an autocrine loop phenomenon was documented through in vitro assays [41]. For BAFF receptors, adipocytes, keratinocytes, and microglia, there are no immune cells with ectopic expression [42,43,44]. In LN murine models, the tubular cells showed mRNA and tissular expression of BAFF receptors [41]. Hence, resident cells could show an ectopic expression of these receptors and amplify local inflammation in patients with LN.
Belimumab, a monoclonal antibody with BAFF targeting, is the only biological treatment approved to treat non-renal clinical domains in SLE [45]. In addition to conventional treatment in LN, Belimumab increases the probability of completing renal remission with a similar rate of adverse events [46,47]. Even in refractory LN, adding Belimumab to the cyclophosphamide and rituximab scheme could improve the renal response with an adequate security profile [48]. The BAFF system expression in resident renal cells and inflammatory infiltrating cells described in this study could support the use of anti-BAFF treatment. Additionally, TACI deletion in murine models is associated with the protection of LN [16].
The main limitations of this study are a reduced number of patients, only the inclusion of proliferative nephritis, the study design, a lack of clinical data, and the absence of labeling of B cells and CXCL13. The information obtained could help generate new therapeutic and diagnostic targets in LN.

5. Conclusions

The expression of BAFF and its receptors is mainly associated with LN class IV, and both inflammatory cells and resident kidney cells are involved in the expression of this system. Together, our results emphasize BAFF system participation as an important pathogenic factor for kidney involvement in SLE patients. However, these results should be taken with caution.

Author Contributions

Conceptualization, M.M.-R. and C.A.P.-S.; methodology, R.A.F.-T., F.J.C.-B., and F.R.-S.; software, F.J.C.-B.; validation, R.A.F.-T.; formal analysis, M.M.-R. and D.C.S.-C.; investigation, M.M.-R. and A.C; resources, A.C. and C.A.P.-S.; data curation, A.C. and D.C.S.-C.; writing—original draft preparation, M.M.-R.; writing—review and editing, J.F.M.-V. and C.A.P.-S.; visualization, R.A.F.-T.; supervision, D.C.S.-C.; project administration, C.A.P.-S.; and funding acquisition, A.C. and C.A.P.-S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Universidad de Guadalajara, grant number PRO-SNI 2018 to A.C. and PRO-SNI 2019 to C.A.P.S.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committees of Hospital General de Occidente under the code CI-561/18 on 14 August 2018.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ortega, L.M.; Schultz, D.R.; Lenz, O.; Pardo, V.; Contreras, G.N. Lupus Nephritis: Pathologic Features, Epidemiology and a Guide to Therapeutic Decisions. Lupus 2010, 19, 557–574. [Google Scholar] [CrossRef] [PubMed]
  2. Hernández Cruz, B.; Alonso, F.; Calvo Alén, J.; Pego-Reigosa, J.M.; López-Longo, F.J.; Galindo-Izquierdo, M.; Olivé, A.; Tomero, E.; Horcada, L.; Uriarte, E.; et al. Differences in Clinical Manifestations and Increased Severity of Systemic Lupus Erythematosus between Two Groups of Hispanics: European Caucasians versus Latin American Mestizos (Data from the RELESSER Registry). Lupus 2020, 29, 27–36. [Google Scholar] [CrossRef] [PubMed]
  3. Soliman, S.; Mohan, C. Lupus Nephritis Biomarkers. Clin. Immunol. 2017, 185, 10–20. [Google Scholar] [CrossRef] [PubMed]
  4. Hahn, B.H.; McMahon, M.A.; Wilkinson, A.; Wallace, W.D.; Daikh, D.I.; Fitzgerald, J.D.; Karpouzas, G.A.; Merrill, J.T.; Wallace, D.J.; Yazdany, J.; et al. American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. Arthritis Care Res. 2012, 64, 797. [Google Scholar] [CrossRef] [Green Version]
  5. Weening, J.J.; D’Agati, V.D.; Schwartz, M.M.; Seshan, S.V.; Alpers, C.E.; Appel, G.B.; Balow, J.E.; Bruijn, J.A.; Cook, T.; Ferrario, F.; et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Kidney Int. 2004, 65, 521–530. [Google Scholar] [CrossRef] [Green Version]
  6. Kostopoulou, M.; Fanouriakis, A.; Cheema, K.; Boletis, J.; Bertsias, G.; Jayne, D.; Boumpas, D.T. Management of Lupus Nephritis: A Systematic Literature Review Informing the 2019 Update of the Joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations. RMD Open 2020, 6, 1–14. [Google Scholar] [CrossRef]
  7. Schneider, P.; Mackay, F.; Steiner, V.; Hofmann, K.; Bodmer, J.-L.; Holler, N.; Ambrose, C.; Lawton, P.; Bixler, S.; Acha-Orbea, H.; et al. BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. J. Exp. Med. 1999, 189, 1747–1756. [Google Scholar] [CrossRef]
  8. Hahne, M.; Kataoka, T.; Schröter, M.; Hofmann, K.; Irmler, M.; Bodmer, J.-L.; Schneider, P.; Bornand, T.; Holler, N.; French, L.; et al. APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth. J. Exp. Med. 1998, 188, 1185–1190. [Google Scholar] [CrossRef] [Green Version]
  9. Ng, L.G.; Sutherland, A.; Newton, R.; Qian, F.; Cachero, T.G.; Scott, M.L.; Thompson, J.S.; Wheway, J.; Chtanova, T.; Groom, J.; et al. B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells. J. Immunol. 2004, 173, 807–817. [Google Scholar] [CrossRef] [Green Version]
  10. Belnoue, E.; Pihlgren, M.; McGaha, T.; Tougne, C.; Rochat, A.-F.; Bossen, C.; Schneider, P.; Huard, B.; Lambert, P.-H.; Siegrist, C.-A. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111, 2755–2764. [Google Scholar] [CrossRef]
  11. Zhang, Y.; Li, J.; Zhang, Y.-M.; Zhang, X.-M.; Tao, J. Effect of TACI Signaling on Humoral Immunity and Autoimmune Diseases. J. Immunol. Res. 2015, 2015, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Mackay, F.; Woodcock, S.A.; Lawton, P.; Ambrose, C.; Baetscher, M.; Schneider, P.; Tschopp, J.; Browning, J. Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations. J. Exp. Med. 1999, 190, 1697–1710. [Google Scholar] [CrossRef] [PubMed]
  13. Vincent, F.; Northcott, M.; Hoi, A.; Mackay, F.; Morand, E. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013, 22, 873–884. [Google Scholar] [CrossRef] [PubMed]
  14. Vincent, F.B.; Kandane-Rathnayake, R.; Koelmeyer, R.; Hoi, A.; Harris, J.; Mackay, F.; Morand, E.F. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin. Transl. Immunol. 2019, 8, e1047. [Google Scholar] [CrossRef] [Green Version]
  15. Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404, 995–999. [Google Scholar] [CrossRef]
  16. Arkatkar, T.; Jacobs, H.M.; Du, S.W.; Li, Q.-Z.; Hudkins, K.L.; Alpers, C.E.; Rawlings, D.J.; Jackson, S.W. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression. Kidney Int. 2018, 94, 728–740. [Google Scholar] [CrossRef] [Green Version]
  17. Santillán-López, E.; Muñoz-Valle, J.F.; Oregon-Romero, E.; Espinoza-García, N.; Treviño-Talavera, B.A.; Salazar-Camarena, D.C.; Marín-Rosales, M.; Cruz, A.; Alvarez-Gómez, J.A.; Sagrero-Fabela, N.; et al. Analysis of TNFSF13B polymorphisms and BAFF expression in rheumatoid arthritis and primary Sjögren’s syndrome patients. Mol. Genet. Genom. Med. 2022, 10, e1950. [Google Scholar] [CrossRef]
  18. Groom, J.; Kalled, S.L.; Cutler, A.H.; Olson, C.; Woodcock, S.A.; Schneider, P.; Tschopp, J.; Cachero, T.G.; Batten, M.; Wheway, J.; et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J. Clin. Investig. 2002, 109, 59–68. [Google Scholar] [CrossRef]
  19. Becker-Merok, A.; Nikolaisen, C.; Nossent, H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006, 15, 570–576. [Google Scholar] [CrossRef]
  20. Morel, J.; Roubille, C.; Planelles, L.; Rocha, C.; Fern, L.; Lukas, C.; Hahne, M.; Combe, B. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann. Rheum. Dis. 2009, 68, 997–1002. [Google Scholar] [CrossRef]
  21. Salazar-Camarena, D.C.; Ortíz-Lazareno, P.; Marín-Rosales, M.; Cruz, A.; Muñoz-Valle, F.; Tapia-Llanos, R.; Orozco-Barocio, G.; Machado-Contreras, R.; Palafox-Sánchez, C.A. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine 2019, 114, 115–127. [Google Scholar] [CrossRef] [PubMed]
  22. Marín-Rosales, M.; Cruz, A.; Salazar-Camarena, D.C.; Santillán-López, E.; Espinoza-García, N.; Muñoz-Valle, J.F.; Ramírez-Dueñas, M.G.; Oregón-Romero, E.; Orozco-Barocio, G.; Palafox-Sánchez, C.A. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin. Exp. Med. 2019, 19, 183–190. [Google Scholar] [CrossRef] [PubMed]
  23. Salazar-Camarena, D.C.; Ortiz-Lazareno, P.C.; Cruz, A.; Oregon-Romero, E.; Machado-Contreras, J.R.; Muñoz-Valle, J.F.; Orozco-López, M.; Marín-Rosales, M.; Palafox-Sánchez, C.A. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 2015, 25, 582–592. [Google Scholar] [CrossRef] [PubMed]
  24. Petri, M.A.; van Vollenhoven, R.F.; Buyon, J.; Levy, R.A.; Navarra, S.V.; Cervera, R.; Zhong, Z.J.; Freimuth, W.W. Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. Arthritis Rheum. 2013, 65, 2143–2153. [Google Scholar] [CrossRef] [PubMed]
  25. Salazar-Camarena, D.C.; Palafox-Sánchez, C.A.; Cruz, A.; Marín-Rosales, M.; Muñoz-Valle, J.F. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Sci. Rep. 2020, 10, 6236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Radin, M.; Miraglia, P.; Barinotti, A.; Fenoglio, R.; Roccatello, D.; Sciascia, S. Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. Am. J. Nephrol. 2021, 52, 559–571. [Google Scholar] [CrossRef]
  27. Suso, J.P.; Posso-Osorio, I.; Jiménez, C.A.; Naranjo-Escobar, J.; Ospina, F.E.; Sánchez, A.; Cañas, C.A.; Tobón, G.J. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus 2018, 27, 708–715. [Google Scholar] [CrossRef]
  28. Petri, M.; Orbai, A.-M.; Alarcón, G.S.; Gordon, C.; Merrill, J.T.; Fortin, P.R.; Bruce, I.N.; Isenberg, D.; Wallace, D.J.; Nived, O.; et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64, 2677–2686. [Google Scholar] [CrossRef]
  29. Carrillo-Ballesteros, F.J.; Oregon-Romero, E.; Franco-Topete, R.A.; Govea-Camacho, L.H.; Cruz, A.; Muñoz-Valle, J.F.; Bustos-Rodríguez, F.J.; Pereira-Suárez, A.L.; Palafox-Sánchez, C.A. B-cell activating factor receptor expression is associated with germinal center B-cell maintenance. Exp. Ther. Med. 2019, 17, 2053–2060. [Google Scholar] [CrossRef] [Green Version]
  30. Chatterjee, S.; Malhotra, R.; Varghese, F.; Bukhari, A.B.; Patil, A.; Budrukkar, A.; Parmar, V.; Gupta, S.; De, A. Quantitative Immunohistochemical Analysis Reveals Association between Sodium Iodide Symporter and Estrogen Receptor Expression in Breast Cancer. PLoS ONE 2013, 8, e54055. [Google Scholar] [CrossRef]
  31. Inês, L.; Duarte, C.; Silva, R.S.; Teixeira, A.S.; Fonseca, F.P.; da Silva, J.A.P. Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-month prospective cohort study. Rheumatology 2014, 53, 85–89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Tektonidou, M.G.; Dasgupta, A.; Ward, M.M. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016, 68, 1432–1441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Kudose, S.; Santoriello, D.; Bomback, A.S.; Stokes, M.B.; D’Agati, V.D.; Markowitz, G.S. Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 2019, 14, 1605–1615. [Google Scholar] [CrossRef] [PubMed]
  34. Rijnink, E.C.; Teng, Y.O.; Wilhelmus, S.; Almekinders, M.; Wolterbeek, R.; Cransberg, K.; Bruijn, J.A.; Bajema, I.M. Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 2017, 12, 734–737. [Google Scholar] [CrossRef] [Green Version]
  35. Phatak, S.; Chaurasia, S.; Mishra, S.K.; Gupta, R.; Agrawal, V.; Aggarwal, A.; Misra, R. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): Potential biomarkers of active lupus nephritis. Clin. Exp. Immunol. 2017, 187, 376–382. [Google Scholar] [CrossRef] [Green Version]
  36. Aguirre-Valencia, D.; Ríos-Serna, L.J.; Posso-Osorio, I.; Naranjo-Escobar, J.; López, D.; Bedoya-Joaqui, V.; Nieto-Aristizábal, I.; Castro, A.M.; Diaz-Ordoñez, L.; Navarro, E.P.; et al. Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers. J. Transl. Autoimmun. 2020, 3, 100027. [Google Scholar] [CrossRef]
  37. Kang, S.; Fedoriw, Y.; Brenneman, E.K.; Truong, Y.K.; Kikly, K.; Vilen, B.J. BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. J. Immunol. 2017, 198, 1600281. [Google Scholar] [CrossRef] [Green Version]
  38. Worthmann, K.; Gueler, F.; von Vietinghoff, S.; Davalos-Mißlitz, A.; Wiehler, F.; Davidson, A.; Witte, T.; Haller, H.; Schiffer, M.; Falk, C.S.; et al. Pathogenetic role of glomerular CXCL13 expression in lupus nephritis. Clin. Exp. Immunol. 2014, 178, 20–27. [Google Scholar] [CrossRef]
  39. Kreimann, K.; Jang, M.-S.; Rong, S.; Greite, R.; Von Vietinghoff, S.; Schmitt, R.; Bräsen, J.H.; Schiffer, L.; Gerstenberg, J.; Vijayan, V.; et al. Ischemia Reperfusion Injury Triggers CXCL13 Release and B-Cell Recruitment After Allogenic Kidney Transplantation. Front. Immunol. 2020, 11, 1204. [Google Scholar] [CrossRef]
  40. Schiffer, L.; Wiehler, F.; Bräsen, J.H.; Gwinner, W.; Greite, R.; Kreimann, K.; Thorenz, A.; Derlin, K.; Teng, B.; Rong, S.; et al. Chemokine CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute T Cell-Mediated Kidney Allograft Rejection. Int. J. Mol. Sci. 2019, 20, 2552. [Google Scholar] [CrossRef]
  41. Schwarting, A.; Relle, M.; Meineck, M.; Föhr, B.; Triantafyllias, K.; Weinmann, A.; Roth, W.; Weinmann-Menke, J. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus 2018, 27, 243–256. [Google Scholar] [CrossRef] [PubMed]
  42. Alexaki, V.-I.; Notas, G.; Pelekanou, V.; Kampa, M.; Valkanou, M.; Theodoropoulos, P.; Stathopoulos, E.N.; Tsapis, A.; Castanas, E. Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Development. J. Immunol. 2009, 183, 5948–5956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Alexaki, V.-I.; Pelekanou, V.; Notas, G.; Venihaki, M.; Kampa, M.; Dessirier, V.; Sabour-Alaoui, S.; Stathopoulos, E.N.; Tsapis, A.; Castanas, E. B-Cell Maturation Antigen (BCMA) Activation Exerts Specific Proinflammatory Effects in Normal Human Keratinocytes and Is Preferentially Expressed in Inflammatory Skin Pathologies. Endocrinology 2012, 153, 739–749. [Google Scholar] [CrossRef] [PubMed]
  44. Kim, K.S.; Park, J.-Y.; Jou, I.; Park, S.M. Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia. J. Leukoc. Biol. 2009, 86, 349–359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Blair, H.A.; Duggan, S.T. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs 2018, 78, 355–366. [Google Scholar] [CrossRef]
  46. Furie, R.; Rovin, B.H.; Houssiau, F.; Malvar, A.; Teng, Y.O.; Contreras, G.; Amoura, Z.; Yu, X.; Mok, C.-C.; Santiago, M.B.; et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N. Engl. J. Med. 2020, 383, 1117–1128. [Google Scholar] [CrossRef]
  47. Shrestha, S.; Budhathoki, P.; Adhikari, Y.; Marasini, A.; Bhandari, S.; Mir, W.A.Y.; Shrestha, D.B. Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis. Cureus 2021, 13, e20440. [Google Scholar] [CrossRef]
  48. Atisha-Fregoso, Y.; Malkiel, S.; Harris, K.M.; Byron, M.; Ding, L.; Kanaparthi, S.; Barry, W.T.; Gao, W.; Ryker, K.; Tosta, P.; et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021, 73, 121–131. [Google Scholar] [CrossRef]
Jcm 12 00071 g001 550
Figure 1. BAFF system expression in lupus nephritis tissues and kidney controls. Glomerular, tubular, and interstitial zones have a positive stain directed to BAFF system members. BR3 and TACI show more stains in the interstitial infiltration. Thus, APRIL was the lowest. The inflammatory cells in the interstitium could simulate an ectopic germinal center. Kidney control tissues did not show expression of BAFF, APRIL, or their receptors. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen.
Figure 1. BAFF system expression in lupus nephritis tissues and kidney controls. Glomerular, tubular, and interstitial zones have a positive stain directed to BAFF system members. BR3 and TACI show more stains in the interstitial infiltration. Thus, APRIL was the lowest. The inflammatory cells in the interstitium could simulate an ectopic germinal center. Kidney control tissues did not show expression of BAFF, APRIL, or their receptors. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen.
Jcm 12 00071 g001
Jcm 12 00071 g002 550
Figure 2. Overall analysis of BAFF system expression in LN. BAFF system expression according to glomerular, tubular, and interstitial zones is illustrated in (a–c). Black circles, black arrows, and white arrows indicate glomerular, tubular, and interstitial BAFF system expression, respectively. The overall expression analysis indicated a higher expression of BAFF and TACI than APRIL. Additionally, BAFF displays a higher expression of BR3 and BCMA (d). The p-value was obtained through Kruskal–Wallis and post hoc tests. Data are shown as the median with IQR. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen, I IQR: Interquartile range.
Figure 2. Overall analysis of BAFF system expression in LN. BAFF system expression according to glomerular, tubular, and interstitial zones is illustrated in (a–c). Black circles, black arrows, and white arrows indicate glomerular, tubular, and interstitial BAFF system expression, respectively. The overall expression analysis indicated a higher expression of BAFF and TACI than APRIL. Additionally, BAFF displays a higher expression of BR3 and BCMA (d). The p-value was obtained through Kruskal–Wallis and post hoc tests. Data are shown as the median with IQR. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen, I IQR: Interquartile range.
Jcm 12 00071 g002
Jcm 12 00071 g003 550
Figure 3. Association of BAFF system expression and proliferative LN classes according to glomerular, tubular, and interstitial zones. Glomerular expression of BR3 and BCMA was higher in class IV and V+V-III/IV groups than in class III; TACI showed a higher expression in class IV compared to class III (c–e). The tubular expression of BAFF was higher in the LN group, mainly in class III (f). The proliferative lesions (class IV) showed a higher expression of BR3, TACI, and BCMA (h–j). Compared to the interstitial BAFF system expression, BAFF, BR3, and TACI displayed higher expressions than the kidney controls (k). The Class IV group had higher expressions of BAFF, BR3, and BCMA (k,m,o). (a,b,g,l,n) did not show a statistical difference (p > 0.05). The p-value was obtained through Kruskal–Wallis and post hoc tests. Data are shown as median with IQR. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen. IQR: Interquartile range, LN: lupus nephritis.
Figure 3. Association of BAFF system expression and proliferative LN classes according to glomerular, tubular, and interstitial zones. Glomerular expression of BR3 and BCMA was higher in class IV and V+V-III/IV groups than in class III; TACI showed a higher expression in class IV compared to class III (c–e). The tubular expression of BAFF was higher in the LN group, mainly in class III (f). The proliferative lesions (class IV) showed a higher expression of BR3, TACI, and BCMA (h–j). Compared to the interstitial BAFF system expression, BAFF, BR3, and TACI displayed higher expressions than the kidney controls (k). The Class IV group had higher expressions of BAFF, BR3, and BCMA (k,m,o). (a,b,g,l,n) did not show a statistical difference (p > 0.05). The p-value was obtained through Kruskal–Wallis and post hoc tests. Data are shown as median with IQR. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen. IQR: Interquartile range, LN: lupus nephritis.
Jcm 12 00071 g003
Jcm 12 00071 g004 550
Figure 4. Matrix correlations of BAFF system expression according to zones. At the glomerular level, APRIL showed a positive correlation between all BAFF system receptors, and TACI correlated with BCMA (a). On the other hand, BR3, TACI, and BCMA showed a positive correlation at the tubular level (b). BCMA expression in the interstitium had a positive correlation with APRIL and TACI (c). The p-value was obtained through a Spearman rank correlation test. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen.
Figure 4. Matrix correlations of BAFF system expression according to zones. At the glomerular level, APRIL showed a positive correlation between all BAFF system receptors, and TACI correlated with BCMA (a). On the other hand, BR3, TACI, and BCMA showed a positive correlation at the tubular level (b). BCMA expression in the interstitium had a positive correlation with APRIL and TACI (c). The p-value was obtained through a Spearman rank correlation test. BAFF: B-cells activating factor, APRIL: A proliferation-inducing ligand, BR3: BAFF receptor, TACI: Transmembrane activator and CALM interactor, BCMA: B-cell maturation antigen.
Jcm 12 00071 g004
Table
Table 1. Histopathological features of proliferative LN tissues.
Table 1. Histopathological features of proliferative LN tissues.
Class III
(n = 5)		Class IV
(n = 6)		Class V and
V+III/IV (n = 5)		Total
(n = 16)		p-Value
Glomerulus, (IQR)23 (14-36)27 (15-33)30 (19-42)25 (18-34)0.837
Histopathological activity index, (IQR)5 (5-6)15 (12-16)5 (4-6)6 (5-14)0.001
Histopathological chronicity index, (IQR)4 (3-4)3 (3-3)3 (2-3)3 (2-3)0.239
Full-house phenomenon, (%)4 (80)6 (100)5 (100)15 (94)0.279
Crescents, (%)2 (40)6 (100)2 (40)10 (62.5)0.056
Glomerular sclerosis, (%)4 (80)4 (67)4 (80)12 (75)0.356
Wire-loop lesions, (%)05 (83)05 (31)0.002
Karyorrhexis, (%)3 (60)6 (100)3 (60)12 (75)0.202
Neutrophilic infiltrated, (%)3 (60)6 (100)3 (60)12 (75)0.202
Hyaline thrombus, (%)1 (20)3 (50)04 (25)0.155
Tubular atrophy, (%)4 (80)6 (100)5 (100)14 (88)0.504
Tubular tumefaction, (%)4 (80)6 (100)5 (100)15 (94)0.309
Tubular-interstitial infiltrated, (%)5 (100)4 (67)3 (60)12 (75)0.288
Tubulointerstitial fibrosis, (%)4 (80)5 (83)4 (80)13 (81)0.986
Data are shown as the median, IQR, frequencies, and percentages, as appropriate. The p-value was obtained using Fisher’s test or Kruskal–Wallis and Dunn’s post hoc test, as appropriate. LN: lupus nephritis, IQR: interquartile range.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Marín-Rosales, M.; Palafox-Sánchez, C.A.; Franco-Topete, R.A.; Carrillo-Ballesteros, F.J.; Cruz, A.; Salazar-Camarena, D.C.; Muñoz-Valle, J.F.; Ramos-Solano, F. Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis. J. Clin. Med. 2023, 12, 71. https://doi.org/10.3390/jcm12010071

AMA Style

Marín-Rosales M, Palafox-Sánchez CA, Franco-Topete RA, Carrillo-Ballesteros FJ, Cruz A, Salazar-Camarena DC, Muñoz-Valle JF, Ramos-Solano F. Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis. Journal of Clinical Medicine. 2023; 12(1):71. https://doi.org/10.3390/jcm12010071

Chicago/Turabian Style

Marín-Rosales, Miguel, Claudia Azucena Palafox-Sánchez, Ramón Antonio Franco-Topete, Francisco Josué Carrillo-Ballesteros, Alvaro Cruz, Diana Celeste Salazar-Camarena, José Francisco Muñoz-Valle, and Francisco Ramos-Solano. 2023. "Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis" Journal of Clinical Medicine 12, no. 1: 71. https://doi.org/10.3390/jcm12010071

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop